About Venus MedTech
Venus MedTech is a publicly listed company based in Hangzhou (China) founded in 2009 by Eric Zi. It operates as a transcatheter aortic and pulmonic valves are developed for cardiovascular procedures. Venus MedTech has raised $37 million across 5 funding rounds from investors including Qiming Venture Partners, DCP and Goldman Sachs Investment Partners. The company has 691 employees. Venus MedTech has completed 5 acquisitions, including InterValve, Keystone Heart and Transcatheter Technologies. Its chief executive is Eric Zi. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Shockwave Medical, Cardiac Dimensions, Pi-Cardia, Symetis and Peijia Medical Technologies and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Venus MedTech is a developer of medical products used during cardiovascular surgeries. Venus Medtech develops and manufactures an advanced interventional artificial cardiac valve system. Additionally, its products include artificial aorta, pulmonary artery, conveying system, compression loading system, etc. Has applied for multiple patents. As of July 2016, Its transcatheter aortic valves have completed clinical trials and follow-up and are pending China Food and Drug Administration (CFDA) clearance, and its transcatheter pulmonic valves are completing it clinical trials. Both of the valves are expected to be the first transcatheter valves approved in China. They are also developing the next-generation heart valves with pre-crimping technology. In 2016, -Transcatheter Technologies a medical device company that has developed a full range of transcatheter valve implantation systems for catheter-based heart valve therapy, announced that it had sold its technology portfolio to Venus Medtech.
- Headquarters Hangzhou, China
- Employees 691
- Founders Eric Zi
- Stage Public
- SectorsHealthcare
- Website venusmedtech.com
- Legal Name Venus Medtech (Hangzhou), Inc. Class H
- Annual Revenue$42.74 M (USD)-34.82as on Dec 31, 2025
- Net Profit-$56.8 M (USD)42.91as on Dec 31, 2025
- EBITDA-$34.66 M (USD)9.46as on Dec 31, 2025
- Total Equity Funding$37M (USD)
in 5 rounds
- InvestorsQiming Venture Partners
& 3 more
- Employee Count691
- Investments & AcquisitionsInterValve
& 4 more
Funding Insights of Venus MedTech
Venus MedTech has successfully raised a total of $37M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37M
- Total Rounds 5
- Investors Count 4
All 5 funding rounds of Venus MedTech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | – | Private Equity Round | – | – | – |
| May 2018 | – | Series C | – | DCP | – |
| Mar 2016 | $37M | Series C | – | – | |
| Nov 2014 | – | Series B | – | – | |
| Apr 2012 | – | Series A | – | – |
4 investors in total: 4 institutional.
Investors in Venus MedTech
Venus MedTech has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiming Venture Partners, DCP and Goldman Sachs Investment Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are managed across multiple sectors by DCP. | – | dcpcapital.com | Beijing, China | |
DNV Capital is engaged in asset management for healthcare and technology industries. | – | dinovacapital.com | Shenzhen, China | |
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
Investments are made in technology-based businesses by this VC firm. | – | gsipventures.com | New York, United States |
Investor details for Venus MedTech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Venus MedTech
1 people are tracked at Venus MedTech (1 in leadership); the tracked headcount is 691.
| Name | Role | Group |
|---|---|---|
Eric Zi | Founder & CEO | Leadership |
Complete people profiles for Venus MedTech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Venus MedTech
Venus MedTech is a publicly listed company on the HKEX with ticker symbol 2500 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Dec 2019
- Listed onHKG: 2500
- Listed entityVenus Medtech (Hangzhou), Inc. Class H
- Exchange sectorHealth technology
- ISINCNE100003PJ8
- Share price1.02 HKD · 2026-10-14
- Market capitalisation449,831,683.00 HKD
- EPS (diluted, trailing year)-1.18 HKD
- Volume (last session)492,500
Financials of Venus MedTech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 332.7M HKD | -442.1M HKD | -269.8M HKD |
| 2024 | 510.5M HKD | -774.5M HKD | -298.0M HKD |
| 2023 | 543.0M HKD | -777.6M HKD | -511.6M HKD |
| 2022 | 472.7M HKD | -1.23B HKD | -669.4M HKD |
| 2021 | 501.2M HKD | -450.3M HKD | -277.4M HKD |
Detailed financial statements for Venus MedTech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Venus MedTech
Venus MedTech has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include InterValve, Keystone Heart and Transcatheter Technologies.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of a novel transcatheter valve replacement system for mitral and tricuspid valve replacement. This system is designed for transfemoral delivery, avoiding open-heart surgery. Key features include a short profile to minimize ventricular protrusion and reduce LVOT obstruction risk, a robust anchoring mechanism, and an enhanced sealing solution to prevent paravalvular leaks. The device is currently limited to investigational use. | cardiovalve.com | Or Yehuda, Israel | 2011 | Dec 2021 | $300M | |
Embolic cerebral protection devices | keystoneheart.com | Tampa, United States | 2004 | Sep 2018 | $100M | |
Aortic valvuloplasty balloons are developed for valve stenosis treatment. | intervalveinc.com | Minneapolis, United States | 2008 | Jun 2017 | •••• | |
Implantable devices for heart valve repair and replacement | transcatheter-technologies.com | Regensburg, Germany | 2009 | Apr 2016 | •••• | |
Catheter-based heart valve implantation and aortic therapy systems are developed. | transcatheter-technology.com | Regensburg, Germany | 2009 | Apr 2016 | •••• |
Complete acquisition details for Venus MedTech
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Venus MedTech
9 dated milestones of Venus MedTech across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Venus MedTech is founded.
- Funding First funding round.
- Acquisition Acquires Transcatheter Technologies.
- Acquisition Acquires Transcatheter Technology.
- Acquisition Acquires InterValve.
- Funding Latest funding round, Private Equity Round,.
- Acquisition Acquires Keystone Heart.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires cardiovalve.
Competitors of Venus MedTech
Venus MedTech has 9 listed competitors in our database, 9 of them funded. They include Shockwave Medical, Cardiac Dimensions, Pi-Cardia, Symetis and Peijia Medical Technologies, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| shockwavemedical.com | 2009 | Santa Clara, United States | $147.5M | 1,394 | Cardiovascular balloon dilation catheters with lithotripsy electrodes are developed. | |
| cardiacdimensions.com | 2001 | Kirkland, United States | $260.8M | 31 | Invasive cardiac implants for heart failure treatment are developed. | |
| pi-cardia.net | 2009 | Rehovot, Israel | $40M | – | Non-implant devices for cardiac valve repair are developed and manufactured. | |
| symetis.com | 2001 | Ecublens, Switzerland | $56.66M | – | Minimally invasive heart valve replacement devices are developed and marketed. | |
| peijiamedical.com | 2012 | Suzhou, China | $110.08M | – | Medical devices for cardiac and cerebrovascular treatments are developed. | |
| jenavalve.com | 2006 | Irvine, United States | $363.7M | 198 | Pericardial transcatheter aortic valve replacement systems are provided. | |
| neochord.com | 2007 | Eden Prairie, United States | $108.67M | 7 | Minimally invasive mitral valve repair devices are developed and provided. | |
| capstanmedical.com | 2020 | Santa Cruz, United States | $141.4M | – | Medical devices for structural heart disease treatment are developed. | |
| tricares.com | 2013 | Aschheim, Germany | $102.84M | – | Minimally invasive tricuspid valve replacement system is developed. |
Detailed competitors of Venus MedTech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Venus MedTech
The website of Venus MedTech (venusmedtech.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▲ 217.4% vs previous month
Top companies in Cardiac and Vascular Disorders
10 companies that operate in the same segment as Venus MedTech (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | – | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Venus Medtech
Complete news archive for Venus MedTech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Venus MedTech
Venus MedTech was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Venus MedTech is headquartered in Hangzhou, China. It is registered at Hangzhou, Zhejiang, China.
Eric Zi is the current CEO of Venus MedTech. They have also founded this company.
Venus MedTech is a funded company, having raised a total of $37M across 5 funding rounds to date.
Venus MedTech has 691 employees.
Annual revenue of Venus MedTech is $42.74M as on Dec 31, 2025.
Venus MedTech is a developer of medical products used during cardiovascular surgeries. Venus Medtech develops and manufactures an advanced interventional artificial cardiac valve system. Additionally, its products include artificial aorta, pulmonary artery, conveying system, compression loading system, etc. Has applied for multiple patents. As of July 2016, Its transcatheter aortic valves have completed clinical trials and follow-up and are pending China Food and Drug Administration (CFDA) clearance, and its transcatheter pulmonic valves are completing it clinical trials. Both of the valves are expected to be the first transcatheter valves approved in China. They are also developing the next-generation heart valves with pre-crimping technology. In 2016, -Transcatheter Technologies a medical device company that has developed a full range of transcatheter valve implantation systems for catheter-based heart valve therapy, announced that it had sold its technology portfolio to Venus Medtech.
Venus MedTech's top competitors include Shockwave Medical, Cardiac Dimensions and JenaValve Technology.
Yes, Venus MedTech is publicly traded on HKEX under the ticker symbol 2500.
Venus MedTech has made 5 acquisitions, including InterValve, Keystone Heart, and Transcatheter Technologies.
Venus MedTech has 4 investors. Key investors include Qiming Venture Partners, DCP, Goldman Sachs Investment Partners, and DNV Capital.